ATM and non-small cell lung carcinoma: In addition, our results shed light on the potential therapeutical benefit of targeting NEDD9, which can be exploited to increase sensitivity to other therapies of value for cisplatin-resistant NSCLC, including PD-1/PD-L1 targeting agents, via mechanisms mediated by NEDD9-ATM-related signaling.